SEC Form 4 · Rule 10b5-1 trading plans
RHYTHM PHARMACEUTICALS, INC. (RYTM)
- 53Trades filed under a plan
- 7Plan adoption dates stated
- 9Quarterly results prints on file
- 0Trades in the days before a print
In the 2025 filing year, RHYTHM PHARMACEUTICALS, INC. filed 31 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 8 reporting owners, covering 53 transactions filed under those plans and 240,108 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 31 names a plan in a footnote. 9 results prints are on file in the same window, which is what makes the interval below measurable.
Trades filed under a plan in RHYTHM PHARMACEUTICALS, INC. 53
- Cramer Pamela J. — 2025-02-04 · S · 902 shares
- Lee Jennifer Kayden — 2025-02-04 · S · 1,447 shares
- Meeker David P — 2025-02-04 · S · 4,278 shares
- Shulman Joseph — 2025-02-04 · S · 1,281 shares
- Smith Hunter C — 2025-02-04 · S · 1,678 shares
- Lee Jennifer Kayden — 2025-02-05 · S · 1,733 shares
- Lee Jennifer Kayden — 2025-02-05 · S · 1,133 shares
- Lee Jennifer Kayden — 2025-02-05 · S · 200 shares
- Lee Jennifer Kayden — 2025-02-10 · S · 1,894 shares
- Lee Jennifer Kayden — 2025-02-10 · S · 2,295 shares
- Cramer Pamela J. — 2025-02-11 · S · 698 shares
- Cramer Pamela J. — 2025-02-11 · S · 3 shares
Plan adoption dates stated in RHYTHM PHARMACEUTICALS, INC. 7
- 2023-02-27 — stated in 16 filings
- 2024-06-25 — stated in 1 filing
- 2024-08-08 — stated in 6 filings
- 2024-12-13 — stated in 1 filing
- 2024-12-16 — stated in 1 filing
- 2025-02-28 — stated in 2 filings
- 2025-03-11 — stated in 2 filings
Quarterly results prints on file in RHYTHM PHARMACEUTICALS, INC. 9
- 2025-01-10
- 2025-02-26
- 2025-05-07
- 2025-08-05
- 2025-11-04
- 2026-01-09
- 2026-02-26
- 2026-05-05
- 2026-08-04
Trades in the days before a print in RHYTHM PHARMACEUTICALS, INC. 0
- 7 days before the 2025-02-26 print — 2025-02-19 · S · Cramer Pamela J. · 982 shares
- 7 days before the 2025-02-26 print — 2025-02-19 · S · German Christopher Paul · 635 shares
- 7 days before the 2025-02-26 print — 2025-02-19 · S · Lee Jennifer Kayden · 2,035 shares
- 7 days before the 2025-02-26 print — 2025-02-19 · S · Meeker David P · 9,896 shares
- 7 days before the 2025-02-26 print — 2025-02-19 · S · Shulman Joseph · 1,228 shares
- 7 days before the 2025-02-26 print — 2025-02-19 · S · Smith Hunter C · 2,215 shares
- 7 days before the 2025-08-05 print — 2025-07-29 · S · Cramer Pamela J. · 1,520 shares
- 13 days before the 2025-02-26 print — 2025-02-13 · S · Lee Jennifer Kayden · 1,205 shares
- 14 days before the 2025-02-26 print — 2025-02-12 · S · Lee Jennifer Kayden · 600 shares
- 14 days before the 2025-02-26 print — 2025-02-12 · S · Lee Jennifer Kayden · 10 shares
- 14 days before the 2025-02-26 print — 2025-02-12 · S · Lee Jennifer Kayden · 1,205 shares
- 14 days before the 2025-02-26 print — 2025-02-12 · S · Shulman Joseph · 462 shares
Interval to the next reported results date
For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.
- 0Within 5 days of a print
- 7Within 10 days of a print
- 7Shortest interval, in days
- 0Trades with no later print on file
- Cramer Pamela J. 2025-02-19 · S · 7 days before the 2025-02-26 print · Chief Human Resources Officer
- German Christopher Paul 2025-02-19 · S · 7 days before the 2025-02-26 print · Corporate Controller & CAO
- Lee Jennifer Kayden 2025-02-19 · S · 7 days before the 2025-02-26 print · EVP, Head of North America
- Meeker David P 2025-02-19 · S · 7 days before the 2025-02-26 print · President and CEO
- Shulman Joseph 2025-02-19 · S · 7 days before the 2025-02-26 print · Chief Technical Officer
- Smith Hunter C 2025-02-19 · S · 7 days before the 2025-02-26 print · Chief Financial Officer
- Cramer Pamela J. 2025-07-29 · S · 7 days before the 2025-08-05 print · Chief Human Resources Officer
Adoption dates, as the filings state them
- 2023-02-27 stated in 16 filings
- 2024-06-25 stated in 1 filing
- 2024-08-08 stated in 6 filings
- 2024-12-13 stated in 1 filing
- 2024-12-16 stated in 1 filing
- 2025-02-28 stated in 2 filings
- 2025-03-11 stated in 2 filings
As the filings state it: “10b5-1 instruction adopted prior to February 27, 2023”
Reported results dates on file
- 2025-01-10
- 2025-02-26
- 2025-05-07
- 2025-08-05
- 2025-11-04
- 2026-01-09
- 2026-02-26
- 2026-05-05
- 2026-08-04
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 1
- FMC CORP 2
- ELI LILLY & Co 4
- ABEONA THERAPEUTICS INC. 2
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 12
- Lifevantage Corp 1
- IONIS PHARMACEUTICALS INC 29
- VERTEX PHARMACEUTICALS INC / MA 22
- ARROWHEAD PHARMACEUTICALS, INC. 9
Order the document
Every company with plan records →
Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.